Redhill histiocytoma images biopharma to present at the bio investor forum 2016, by @nasdaq

TEL-AVIV, israel, oct. 13, 2016 (GLOBE NEWSWIRE) — redhill biopharma ltd. (NASDAQ:RDHL) (TASE:RDHL) (“redhill” or the “company”), a biopharmaceutical company primarily focused on development and commercialization of histiocytoma images late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that mr. Dror ben-asher, redhill’s chief executive officer, will present at the BIO investor forum 2016, on tuesday, october 18, 2016, at 10:30 am PDT, at the westin st. Francis hotel, san francisco, CA.

RedHill biopharma ltd. (NASDAQ:RDHL) (TASE:RDHL) is a biopharmaceutical company headquartered in israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory histiocytoma images diseases and cancer. RedHill’s current pipeline of proprietary products includes: (i) RHB-105 – an oral combination therapy for the treatment of helicobacter pylori histiocytoma images infection with successful results from a first phase III study; (ii) RHB-104 – an oral combination therapy for the treatment of crohn’s disease with an ongoing first phase III study and histiocytoma images an ongoing proof-of-concept phase iia study for multiple sclerosis; (iii) BEKINDA ® (RHB-102) – a once-daily oral pill formulation of ondansetron with an ongoing phase histiocytoma images III study for acute gastroenteritis and gastritis and an ongoing histiocytoma images phase II study for IBS-D; (iv) RHB-106 – an encapsulated bowel preparation licensed to salix pharmaceuticals, ltd.; (v) YELIVA ™ (ABC294640) – a phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications; (vi) MESUPRON – a phase II-stage first-in-class, orally-administered upa inhibitor, targeting gastrointestinal and other solid tumors; (vii) RP101 – currently subject to an option-to-acquire by redhill, RP101 is a phase II-stage first-in-class, orally-administered hsp27 inhibitor, targeting pancreatic and other gastrointestinal cancers; (viii) RIZAPORT ® (RHB-103) – an oral thin film formulation of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization histiocytoma images received in germany in october 2015; and (ix) RHB-101 – a once-daily oral pill formulation of the cardio drug carvedilol.

This press release contains “forward-looking statements” within the meaning of the private securities litigation reform act histiocytoma images of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject histiocytoma images to various known and unknown risks and uncertainties, many of which are beyond the company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied histiocytoma images by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the initiation, timing, progress and results of the company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts; (ii) the company’s ability to advance its therapeutic candidates into clinical trials histiocytoma images or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the company histiocytoma images may be required to conduct and the company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the company’s therapeutic candidates; (v) the company’s ability to establish and maintain corporate collaborations; (vi) the company’s ability to acquire products approved for marketing in the histiocytoma images U.S. That achieve commercial success and build its own marketing and histiocytoma images commercialization capabilities; (vii) the interpretation of the properties and characteristics of the company’s therapeutic candidates and of the results obtained with its histiocytoma images therapeutic candidates in research, preclinical studies or clinical trials; (viii) the implementation of the company’s business model, strategic plans for its business and therapeutic candidates; (ix) the scope of protection the company is able to establish histiocytoma images and maintain for intellectual property rights covering its therapeutic candidates histiocytoma images and its ability to operate its business without infringing the histiocytoma images intellectual property rights of others; (x) parties from whom the company licenses its intellectual property defaulting histiocytoma images in their obligations to the company; (xi) estimates of the company’s expenses, future revenues capital requirements and the company’s needs for additional financing; (xii) competitive companies and technologies within the company’s industry; and (xiii) the impact of the political and security situation in israel histiocytoma images on the company’s business. More detailed information about the company and the risk factors histiocytoma images that may affect the realization of forward-looking statements is set forth in the company’s filings with the securities and exchange commission (SEC), including the company’s annual report on form 20-F filed with the SEC on february 25, 2016. All forward-looking statements included in this press release are made only histiocytoma images as of the date of this press release. We assume no obligation to update any written or oral histiocytoma images forward-looking statement unless required by law. Company contact: